Kornimate/medical-research-clean huggingface dataset:
unilateral versus bilateral neuromodulation tests in the treatment of refractory idiopathic overactive bladder

Conditions: Urinary Bladder, Overactive

Summary: the primary objective of this study is to compare the efficacy of unilateral and bilateral neuromodulation tests at 1 month.

the secondary objectives of this study are to compare the following elements between a group of patients undergoing unilater modulation tests (standard procedure) and a group of patients undergoing bilateral neuromodulation tests (experimental procedure) (at 1 month): pollakiuria, pad use, urge incontinence, symptom severity, % of patients not eligible for an implant, debimetry, tolerance, complications, quality of life.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 1 month of follow-up * the patient understands and reads french * the patient has symptoms of overactive bladder resistant to first-line treatments (physiotherapy, anticholinergics) * the patient suffers from an overactive bladder confirmed by a urodynamic panel * the patient suffers from an overactive bladder unassociated with bladder obstruction as confirmed by flowmetry * the patient has primary (idiopathic) overactive bladder primary with normal urinalysis, abdominal and pelvic ultrasound, urine cytology + / - cystoscopy * the patient has no bleeding disorders, or the disorder is properly controlled after treatment exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * overactive bladder associated with bladder obstruction as determined by flowmetry * overactive bladder unconfirmed by urodynamic panel * overactive bladder secondary to another condition: * vesical: urolithiasis, bladder polyp, interstitial cystitis * pelivienne: tumor or inflammatory * neurological: multiple sclerosis, brain tumor, epilepsy * the patient has an uncorrectable bleeding disorder

Keywords: refractory overactive bladder neuromodulation sacral nerves
subconjunctival bevacizumab and recurrent pterygium

Conditions: Recurrent Pterygium

Summary: a study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

1. pacients with recurrent pterygium 2. anti-vegf therapy -bevacizumab

Eligibility criteria:
inclusion criteria: * recurrent pterygium exclusion criteria: * pregnant or lactating women * history of myocardial infarction * history of stroke

Keywords: subconjunctival bevacizumab recurrent pterygium
pilot study comparing the safety and efficacy of two dosing regimens of tp-03 for the treatment of mgd

Conditions: Meibomian Gland Dysfunction; Blepharitis; Demodex Infestation

Summary: the purpose of this study is to compare the safety and efficacy of tp-03, 0.25%, an eyedrop, bid vs tid dosing regimens for the treatment of meibomian gland dysfunction in patients with demodex lid infestation.

this phase 2a study is a randomized, two-arm, double-masked, multicenter, parallel pilot study to compare the safety and efficacy of two dosing regimens of tp-03, bid vs tid, for the treatment of meibomian gland dysfunction in patients with demodex lid infestation. the primary objective of the study is to assess the safety and efficacy of two dosing regimens of tp-03, 0.25% from day 1 to day 85 in adult participants with meibomian gland dysfunction in the presence of demodex infestation. efficacy will be determined by assessing lower lid meibomian gland secretion, lid margin erythema, bulbar redness, tear breakup time, ocular surface staining, and dry eye symptoms. safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity and slit lamp biomicroscopy from baseline.

Eligibility criteria:
inclusion criteria: * be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol * meets all of the following criteria in at least one eye: have more than 10 lashes with collarettes present on the upper lid; have the presence of one or more mites in the upper and lower lids; have evidence of meibomian gland dysfunction; have at least mild erythema of the lower lid; have a tear breakup time of less than 10 seconds; and have intact partial to full meibomian glands in at least 33% of the total meibomian gland area of the lower lid exclusion criteria: * have used lid hygiene products within 7 days of day 1 or unwilling to forego the use of lid hygiene products during the study * have used systemic antihistamines within 30 days of day 1 * have used artificial eyelashes, eyelash extensions or had other cosmetic eyelash or eyelid procedures within 7 days of day 1 or be unwilling to forego their use during the study * contact lens wear within 7 days of day 1 or unwilling to forego contact lens wear for the duration of the study * be pregnant or lactating at day 1

Keywords: demodex
samples procurement for colorectal cancer, gastric cancer, and non-malignant disease

Conditions: Colorectal Cancer; Gastric Cancer; Inflammatory Bowel Diseases; Gastric Ulcer; Hemorrhoids; Hernia

Summary: the purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and/or normal gastrointestinal tissue (if available) from patients with non-malignant disease (including, but not limited to, inflammatory bowel disease (ibd), gastric ulcer, hemorrhoids or hernia), and to create a database for the collected samples and allow access to relevant clinical information for current and future protocols.


Eligibility criteria:
inclusion criteria: * any patient diagnosed with colorectal cancer, gastric cancer, non-malignant disease that requires undergoing surgery. * must be willing and able to provide informed consent. exclusion criteria: * subjects whose comorbidities would preclude diagnostic or therapeutic intervention.
uk - ehl outcomes registry

Conditions: Hemophilia A; Hemophilia B

Summary: severe haemophilia a and b (sha, shb) are inherited bleeding disorders affecting male patients and are characterised by low levels of circulating clotting factors viii and ix respectively. clinically low levels present with multiple recurrent bleeds into joints and muscle from the first couple of years of life. in addition patients may present with spontaneous and potentially fatal bleeding into any organ. the mainstay of treatment is replacement with the missing factor in the form of intravenous injections of factor viii and ix. clotting factors can be given to treat a bleed or can be given to prevent a bleed, and the latter is termed prophylaxis. regular prophylaxis is the current standard of care and aims to decrease spontaneous bleeding events and resulting joint damage, and this requires patients to self-infuse factor into their veins two to four times week. patient's compliance with prescribed regimen and recommendations has a significant influence on outcomes. advances in biomolecular and protein engineering have extended the duration of the effect of clotting factor viii and ix through multiple mechanisms. this extension of the duration of the effect presents the clinician and patients with opportunities to tailor the treatment to their particular needs, circumstances and body other characteristics. it has been suggested that decreasing the frequency of infusions will improve adherence and thus contribute to improved outcomes. in rare disorders, it is an accepted fact that post-marketing studies are crucial to understand the generalisability of the efficacy and safety outcomes and identify any new safety and efficacy concerns in relation to specific population group. the investigators propose the development of a registry for systematic collection of information with the dual aim of analysing the relationship between patient and treatment characteristics, and outcomes, and simultaneously identify areas for practice development that can improve the overall quality of life experienced by the haemophilia patient community.


Eligibility criteria:
inclusion criteria: 1. patients with haemophilia a or b requiring replacement therapy 2. patients or parents able to provide informed consent 3. patients being considered for use of ehl - cfc. exclusion criteria: 1. patients currently enrolled into a clinical trial of investigational medicinal product.

Keywords: hemophilia
the angle of the metacarpophalangeal joint of the thumb during maximal pinch strength

Conditions: Post-traumatic; Arthrosis; Osteoarthritis Thumb

Summary: the aim of the study is to measure the position of the metacarpophalangeal joint of the thumb during key-pinch, tripod-pinch and opposition-pinch in normal volunteers, to determine the optimal position of metacarpophalangeal joint arthrodesis.

the aim of the study is to measure the position of the metacarpophalangeal (mcp) joint of the thumb during key-pinch, tripod-pinch and opposition-pinch in normal volunteers, to determine the optimal position of metacarpophalangeal joint arthrodesis. the force will be measured in three positions (key-pinch, tripod-pinch and opposition-pinch). also measured is the degree of flexion of the mcp joint of the thumb. the mobility of the mcp joint of the thumb in maximum flexion and extension will also be measured. a total of about 300 healthy volunteers will be examined, with no history of trauma or disease to tendons or joints of the thumbs and between the ages of 18 and 40. the sponsor of this study is professor nadine hollevoet. master students of medicine from the faculty of medicine and health sciences will be part of the research team.

Eligibility criteria:
inclusion criteria: * age between 18 and 40 years exclusion criteria: * (previous) pathology of the joints, ligaments or tendons of the thumb
effects of exercise training and ketone ester on muscle strength and cardiovascular response in parkinson's disease

Conditions: Parkinson Disease

Summary: the main purpose of this study is to assess changes in exercise capacity in people with parkinson's disease before and after an exercise training program with ketone ester supplementation.


Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease exclusion criteria: * any recent changes in ekg, history of myocardial infarction or other cardiac event or other cardiac contraindications to exercise * inability to use a step, stand, walk, or use a stationary cycle ergometer * history of symptoms in exercise that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, painful neuropathy, significant ankle edema or medication side effects * history of symptomatic cardiovascular or pulmonary disease interfering with exercise * history of active rheumatoid arthritis * history of uncontrolled chronic pain syndrome * any other history of medical or psychiatric comorbidity precluding safe participation in the project * poorly controlled diabetes * pregnancy or breastfeeding * clinically significant dementia * any contraindications to mri (metal implants, severe claustrophobia, inability to lie still for 1 hour, etc.)

Keywords: exercise ketone ester keto
trial on effectiveness combined probiotics in atopic dermatitis in children

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is an immune disorder, characterized by chronic skin inflammation or relapsing, whose prevalence is increasing worldwide. its exact etiology remains unknown. the hypothesis that an appropriate early stimulation of the intestinal flora contributes to the establishment of the immune system balance has led to the use of probiotics in the prevention and treatment of ad in several clinical and experimental studies. therefore, the objectives of this study will evaluate the clinical efficacy of the mixture of probiotics (lactobacillus and bifidobacterium) in children with ad through the scorad (scoring atopic dermatitis) and to evaluate the effects of this medication in the following laboratory parameters: skin prick test, total serum immunoglobulin e (ige), inflammation composite (interferon gamma \[ɣ - ifn\], interleukins \[il1-β, il-4, il-6, il-8\] and tumor necrosis factor alpha) and immune tolerance composite (il-10, il-17 and transforming growth factor beta \[tgf - β\]).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of atopic dermatitis * children over 6 months. * teens lower than 19 years no inclusion / exclusion criteria: * diagnostic presence or clinical signs suggesting acute or chronic skin diseases, as well as pertinent to the study, which may affect the outcome of the research. * being in use of drugs that can affect systemically in the course of the disease, such as systemic corticosteroids and immunosuppressants, for at least 30 days. * allergy or severe adverse reactions attributable to the administration of the probiotic. * non adherence to treatment (ie not present regular use, as prescribed) for at least one continuous month. * lack of attendance by more than 50% of ratings (clinical and/or laboratory) to be held during the search. * patient's request (or responsible's request)

Keywords: probiotics inflammation awareness immune tolerance
the efficacy of enteric-coated mycophenolate sodium (ec-mps) (myfortic) in the treatment of relapse or resistant proliferative lupus nephritis

Conditions: Lupus Nephritis

Summary: to investigate the efficacy and safety of enteric-coated mycophenolate sodium (myfortic) as compared to intravenous cyclophosphamide in the treatment of active nephritis. the primary outcomes are complete and partial renal remission, as assessed by renal function, urinary sediment and proteinuria in patients with international society of nephrology/ renal pathology society (isn/rps) class iii or iv lupus nephritis.

in this study, there are two sub-studies in order to define secondary endpoints. 1. pharmacokinetics study of mycophenolic acid 2. identify biomarkers for therapy-resistant prediction. 3. identify biomarkers for predicting a loss of kidney function.

Eligibility criteria:
inclusion criteria: * age 16 years of above at the time of screening * ability and willingness to provide written informed consent (or to obtain consent from parent guardian where applicable) and to comply with the schedule of protocol requirements * diagnosis of sle according to acr criteria. at least 4 criteria must have been present for the diagnosis of sle. the 4 criteria do not have to be present at the time of screening * active lupus nephritis defined as follows: biopsy proven (within 16 weeks prior to screening) isn class iii or iv (a or a/c) not include iii(c) iv(c) and vi (\>90% chronic irreversible scarring) * relapse or resistant to (3 consecutive doses) ivcy * resistant lupus or relapse lupus nephritis defined as follows: * increase in serum creatinine \>/= 0.3 mg/dl or * increase in proteinuria \> 1.5 g/day (which must have improved by ≥ 50% in the preceding 3 months) * life-time cumulative dose of ivcy \> 6 grams * female patients of childbearing potential must have a negative serum pregnancy exclusion criteria: relates to sle * diagnosis of rapid progressive glomerulonephritis (rpgn): doubling serum creatinine and/or crescentic glomeruli ≥ 30% * severe renal impairment as defined by calculated creatinine clearance or mdrd-gfr \ 50 ml/min in the 12 weeks prior to screening) * history of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups. * severe extra-renal organ involvement related to treatment * previous of any mycophenolate groups in the 6 months prior to screening * treatment with any investigational drugs in the 3 months prior to screening related to general health * pregnancy or breast feeding mothers. * concomitant condition which has required treatment moderate to high dose steroid in the 12 weeks prior to screening. * evidence of significant uncontrolled concomitant disease in any organ system not related to sle. * history of cancer, including solid tumors, hematological malignancies and carcinoma. * evidence of current abuse of drugs or alcohol. related to laboratory findings * neutrophile \< 1,500/mm3, hb \< 7g/l, platelet \< 50,000/mm3 (except active sle) * positive hbsag or anti-hcv or anti-hiv.

Keywords: lupus nephritis mycophenolate sodium cyclophosphamide
isometric handgrip exercise for blood pressure management

Conditions: Hypertension

Summary: the aim of this project is to conduct a randomised controlled trial to assess the effect of performing isometric exercise using a handgrip dynamometer on blood pressure.

recent meta-analyses suggest isometric resistance training (irt) may be superior to aerobic exercise for lowering blood pressure. a randomised controlled study will be conducted with participants who are either pre-hypertensive, blood pressure between 120/80 and 140/90, or on medication to control their blood pressure. previous studies have utilised a sedentary control so we intend to use a sham group to determine if it can be used as a working control for future studies.

Eligibility criteria:
inclusion criteria: * those within the required age limits, both normotensive, pre-hypertensive, and those medicated for blood pressure management. exclusion criteria: * younger than 30 years and older than 70 years; those deemed not to have the capacity to voluntarily participate, unable to participate under their doctor's recommendation, or with arthritis or carpal tunnel syndrome who may aggravate their condition with handgrip exercise.
oral tranexamic acid plus sublingual misoprostol in atonic postpartum hemorrhage

Conditions: Post Partum Hemorrhage

Summary: the aim of the study is to evaluate the effect of oral tranexamic acid plus, sublingual misoprostol in the management of atonic postpartum hemorrhage (pph) after vaginal delivery

uterine atony is the main cause of pph; therefore, active management of the third stage of labor has emerged as a most actual tool in its prevention. the previous study in egypt recorded that 88% of deaths from pph occur within 4 h of delivery. tranexamic acid (ta) is an antifibrinolytic agent that blocks the lysine-binding site of plasminogen to fibrin. accordingly, clot breaks down, fibrinolysis is inhibited, and excessive bleeding is reduced. in previous studies, its safety has been confirmed for use in non-pregnant women, with no thromboembolic complications. ta is an inexpensive, widely available medicine that has been shown to reduce bleeding in surgery and reduce the risk of death in bleeding trauma patients.

Eligibility criteria:
inclusion criteria: * all participants had pph defined as vaginal bleeding\>500 ml after vaginal delivery and uterine atony confirmed by abdominal palpation. exclusion criteria: * were gestational age\<37 weeks, * genital tract trauma, * coagulation defect, * women with hypertension, preeclampsia, cardiac, renal or liver diseases, epilepsy * known hypersensitivity to carbetocin or oxytocin.

Keywords: postpartum hemorrhage vaginal delivery tranexamic acid misoprostol
trial on two treatments for adolescent idiopathic scoliosis

Conditions: Scoliosis; Adolescence

Summary: adolescent idiopathic scoliosis is a three-dimensional structural deformity of the spine and pelvic that occurs in children. more evidence has arisen to emphasize the important role played by pelvic asymmetry during the progression of scoliosis. the purpose of this study is to compare the effectiveness of pelvic adjustments accompanied with schroth-based exercises, with the latter alone in adolescent idiopathic scoliosis, to assess the impact of pelvic asymmetry on the spinal three-dimensional parametric features in scoliosis.

adolescent idiopathic scoliosis is the most common three-dimensional structural deformity of the spine among adolescence, the international society on scoliosis orthopaedic and rehabilitation treatment recommend specific exercise therapy to delay the progression of scoliosis. many specific exercise therapies are effective in reducing the angle of coronal scoliosis, but their efficiency in sagittal and axial deformities hasn't been convincing. recent studies have found that the axial asymmetry of the pelvis may be involved in the pathogenesis of idiopathic scoliosis, but there is no clinical study on the treatment of scoliosis by correcting the axial torsion of the pelvis neither at home nor abroad. so in this study, "3 plus 1" multidimensional exercise therapy was applied to mild adolescent idiopathic scoliosis for the first time. the present study is a single-center randomized controlled trial conducted at the department of rehabilitation medicine, aerospace center hospital. the written informed consent will be obtained from each patient and one of their parents before inclusion. eligible subjects will be randomized by a 1:1 allocation ratio either to the experimental group, in which the "3 plus 1" multidimensional exercise therapy will be performed and pelvic correction technique was adopted to correct pelvic axial rotation, or the control group, in which they will receive the schroth-based exercise therapy. blinded assessments will be conducted at baseline and 6-month after the intervention, including the differences in three-dimensional structural parameters of pelvis and spine, such as the ratio of the iliac widths, srs-22 questionnaire, etc, to compare the efficacy of two different groups in improving the three-dimensional balance of the spine and the quality of daily life in adolescent idiopathic scoliosis.

Eligibility criteria:
inclusion criteria: * a diagnosis of adolescent idiopathic scoliosis; age from 10 to 18 years; a cobb angle of 10 to 25 degrees; all maturity levels (risser sign of 0-5). exclusion criteria: * non-idiopathic scoliosis, which is caused by a neuromuscular, neurological, congenital malformation, or trauma-related comorbidity; having mental problems or other contraindications to exercise; previous fractures, rheumatic diseases, or operation history of lower extremities; previous or current brace or surgical treatments for scoliosis.
the effects of fragility fracture integrated rehabilitation management

Conditions: Hip Fractures

Summary: • to determine the effects of fragility fracture integrated rehabilitation management approach in geriatric hip fracture patients (post surgical)

this refers to fragility fracture integrated rehabilitation management and will include following comprehensive rehabilitation program including rehab specialist, physiotherapist, occupational therapist and rehab nurse.

Eligibility criteria:
inclusion criteria: 1. patients above 55 years of age, who underwent hip fracture management nirm pakistan due to hip fracture 2. patient diagnosed with femur neck, intertrochanteric fracture, and sub-trochanteric fracture 3. patient who got bipolar hemiarthroplasty, total hip replacement arthroplasty, reduction and internal fixation exclusion criteria: 1. patients who underwent surgery for a cause other than a hip fracture (infection, arthritis, loosening, avascular necrosis) 2. patients who underwent surgery because of femur shaft fracture, acetabular fracture, periprosthetic fracture pathologic fracture by tumor 3. isolated fracture of the greater or lesser tuberosity 4. multiple fracture 5. revision operation 6. patients who do not agree to participate in clinical trials

Keywords: activities of daily living mobility limitation occupational therapy physical therapy